The city of Los Angeles, California, currently has 12 active clinical trials seeking participants for Epilepsy research studies.
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2024
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Focal Epilepsy
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Recruiting
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/15/2024
Locations: Sanguine Biosciences, Los Angeles, California
Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Epilepsy Learning Healthcare System (ELHS)
Recruiting
The Epilepsy Learning Health System (ELHS) is a quality improvement and research network to improve outcomes for people with epilepsy. The ELHS is designed as a model of value-based chronic care for epilepsy as envisioned by the National Academies of Medicine Committee in their landmark reports "The Learning Health System" and "Epilepsy Across the Spectrum: Promoting Health and Understanding". The ELHS network is a collaboration among clinicians, patients and researchers that promotes the use o... Read More
Gender:
All
Ages:
All
Trial Updated:
02/15/2024
Locations: University of Southern California, Los Angeles, California
Conditions: Epilepsy, Seizure Disorder, Neurologic Disorder, Rare Diseases
Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)
Recruiting
The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: University of California Los Angeles (UCLA), Los Angeles, California
Conditions: Epilepsy
FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
Recruiting
This clinical trial is designed to test whether a single stereotactic intracerebral administration of inhibitory nerve cells into subjects with drug-resistant mesial temporal lobe epilepsy is safe (frequency of adverse events) and effective (seizure frequency).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/19/2024
Locations: University of California Los Angeles, Los Angeles, California
Conditions: Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis
Exercise for Brain Regeneration in Epilepsy
Recruiting
Nearly 100 million Americans are affected by neurological disorders with an overall cost above $765 billion for the more prevalent conditions. Given this significant burden, effective treatments to prevent dementia and new disease modifying therapies are urgently needed. Regeneration of lost neurons with new ones (i.e., neurogenesis) is compromised at early stages of dementia and in part correlates with cognitive impairment in Alzheimer's disease. Boosting the neurogenesis delays the cognitive... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/05/2023
Locations: University of Southern California Department of Neurosurgery, Los Angeles, California
Conditions: Temporal Lobe Epilepsy
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
Recruiting
The purpose of the study is to evaluate the efficacy of lacosamide (LCM) versus an Active Comparator chosen based on standard of care (StOC) in severe and nonsevere seizure burden (defined as total minutes of electroencephalographic neonatal seizures (ENS) per hour) in neonates with seizures that are not adequately controlled with previous anti-epileptic drug (AED) treatment.
Gender:
All
Ages:
28 days and below
Trial Updated:
11/20/2023
Locations: Sp0968 116, Los Angeles, California
Conditions: Electroencephalographic Neonatal Seizures, Epilepsy
Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients With Temporal Lobe Epilepsy
Recruiting
The 24/7 EEG™ SubQ system will be compared to simultaneously recorded video-EEG in the Epilepsy Monitoring Unit (gold standard) and to self-reported seizure log books throughout 12 weeks of outpatient EEG recording. The present study is a 12-week open-label, prospective study with a paired, comparative design for pivotal evaluation of the safety and effectiveness of the 24/7 EEGTM SubQ system in subjects with temporal lobe epilepsy. 2-5 sites in Europe Up to 5 sites in US, or up to 10 sites if... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/20/2023
Locations: University of California, Los Angeles, California
Conditions: Epilepsy
Model-based Electrical Brain Stimulation
Recruiting
Neuropsychiatric disorders are a leading cause of disability worldwide with depressive disorders being one of the most disabling among them. Also, millions of patients do not respond to current medications or psychotherapy, which makes it critical to find an alternative therapy. Applying electrical stimulation at various brain targets has shown promise but there is a critical need to improve efficacy. Given inter- and intra-subject variabilities in neuropsychiatric disorders, this study aims to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: University of Southern California, Los Angeles, California
Conditions: Medication Refractory Epilepsy Patients With Electrodes Already Implanted Based on Clinical Criteria for Standard Monitoring
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
Recruiting
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants. This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).
Gender:
All
Ages:
Between 1 day and 6 months
Trial Updated:
08/21/2023
Locations: University of California at Los Angeles, Los Angeles, California
Conditions: Tuberous Sclerosis Complex, Epilepsy
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
Recruiting
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an additional 10 weeks post treatment. Quality of Life questionnaires and adverse even... Read More
Gender:
All
Ages:
9 years and above
Trial Updated:
07/21/2023
Locations: Keck Medicine of USC, Los Angeles, California
Conditions: Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Recruiting
Humans have a remarkable ability to flexibly interact with the environment. A compelling demonstration of this cognitive flexibility is human's ability to respond correctly to novel contextual situations on the first attempt, without prior rehearsal. The investigators refer to this ability as 'ad hoc self-programming': 'ad hoc' because these new behavioral repertoires are cobbled together on the fly, based on immediate demand, and then discarded when no longer necessary; 'self-programming' becau... Read More
Gender:
All
Ages:
Between 10 years and 64 years
Trial Updated:
04/14/2023
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Epilepsy